This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
August 3, 2012, 08:00 am ET
Carol Hausner - Executive Director, IR & Corporate Communications
Dan Junius - President & CEO
Greg Perry - EVP & CFO
Jim O'Leary - VP & CMO
Thomas Wei - Jefferies
Adnan Butt - RBC Capital Markets
Mara Goldstein - Cantor Fitzgerald
John Sonnier - William Blair
Ling Wang - Summer Street Partners
Boris Peaker - Oppenheimer
Cory Kasimov - JPMorgan
Yale Jen - Roth Capital Partners
David Miller - Biotech Stock Research
Good day and welcome everyone to this ImmunoGen, fourth quarter fiscal year 2012 financial results conference call. Today’s call is being recorded. At this time, for opening remarks and introductions, I would like to turn the call over to the Executive Director, Investor Relations and Corporate Communications, Carol Hausner. Please go ahead.
Thank you. Good morning. At 6:30 am this morning, we issued a press release that summarizes our financial results for our fourth quarter and fiscal year ended June 30, 2012. I hope you have all had a chance to review it, if not; it’s available on our website.
During today’s call we will make forward-looking statements. Our actual results may differ materially from such statements. Descriptions of the risks and uncertainties associated with an investment in ImmunoGen are included in our SEC filings, which also can be accessed through our website.
In our call today, our Chief Executive Officer, Dan Junius, will provide an update on ImmunoGen and our Chief Financial Officer, Greg Perry, will discuss our financial results and guidance for our fiscal year 2013. We will then open the call to questions. Our Chief Medical Officer Dr. Jim O'Leary will be available for the question-and-answer session. Dan?